These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 21435189)

  • 41. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
    Rai P; Kumar P; Mishra S; Aggarwal R
    Indian J Gastroenterol; 2016 Sep; 35(5):366-371. PubMed ID: 27633031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
    Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
    Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
    [No Abstract]   [Full Text] [Related]  

  • 46. Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.
    Mishcheniuk OY; Kostukevich OM; Dmytrenko IV; Sholoyko VV; Prokopenko IM; Martina ZV; Pilipenko GV; Klymenko SV
    Exp Oncol; 2013 Sep; 35(3):202-6. PubMed ID: 24084459
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
    Foucar CE; Stein BL
    JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
    [No Abstract]   [Full Text] [Related]  

  • 48. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings.
    Colaizzo D; Amitrano L; Iannaccone L; Vergura P; Cappucci F; Grandone E; Guardascione MA; Margaglione M
    J Med Genet; 2007 Jun; 44(6):412-6. PubMed ID: 17307838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
    Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
    Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis.
    Goodyer M; Langabeer SE; Haslam K; Murphy K
    Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123
    [No Abstract]   [Full Text] [Related]  

  • 52. [Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm].
    Xia L; Ding KY; Cai XY; Zhu WB; Liu X; Yang HZ; Wan X; Wu LL; Zeng QS; Wu JS
    Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):590-3. PubMed ID: 21122317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
    Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
    Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder.
    Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A
    Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706
    [No Abstract]   [Full Text] [Related]  

  • 55. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Thrombosis in myeloproliferative neoplasms].
    Asakura H
    Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
    Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
    Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
    How J; Zhou A; Oh ST
    Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.